title: Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
abstract: This review summarizes published data on sofosbuvir-based regimens for patients infected with HCV GT1 with a focus on evaluating the optimal and possible durations of treatment.
  
  
  METHODS
  PubMed and conference abstract books published between 2011-2015 were searched.
  
  
  RESULTS
  HCV treatment has decreased from 24 week regimens to studies done as short as 4 weeks. History of prior treatment or cirrhosis have consistently shown lower SVR12 rates with shorter duration therapies. Low cure rates have been seen in patients within 4 week trials, however, select patients with low fibrosis scores, low HCV VL and HCV GT-1b have moderate cure rates.
  
  
  CONCLUSIONS
  Most patients will require 12-24 weeks of therapy. Further studies are needed to elucidate the predictors of treatment response to short duration therapies and optimal combination of DAAs.
authors.affiliation: a Department of Hepatology, Dignity Health , St. Joseph's Hospital , Phoenix , AZ , USA.
authors.forename: Shirin
authors.initials: S
authors.lastname: Nafisi
authors.affiliation: b Department of Internal Medicine, Dignity Health , St. Joseph's Hospital , Phoenix , AZ , USA.
authors.forename: Sabyasachi
authors.initials: S
authors.lastname: Roy
authors.affiliation: a Department of Hepatology, Dignity Health , St. Joseph's Hospital , Phoenix , AZ , USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Gish
authors.affiliation: a Department of Hepatology, Dignity Health , St. Joseph's Hospital , Phoenix , AZ , USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Manch
authors.affiliation: a Department of Hepatology, Dignity Health , St. Joseph's Hospital , Phoenix , AZ , USA.
authors.forename: Anita
authors.initials: A
authors.lastname: Kohli
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D019468:Disease Management; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005449:Fluorenes / Q000627:therapeutic use; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000472:pathogenicity / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control* / Q000821:virology; D012367:RNA, Viral / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D012254:Ribavirin / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; D012367:RNA, Viral; C586541:ledipasvir; D012254:Ribavirin; D000069474:Sofosbuvir
keywords: (5-10): sofosbuvir; IFN free regimens; NS5B inhibitor; directly acting antivirals; duration; genotype 1; hepatitis C